ENGOT-cx8 / InnovaTV 205 / GCT1015-05 / GOG-3024

About this trial

This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.

The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.

Patient Profile

Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, University Hospital Galway, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: ENGOT-cx8 / InnovaTV 205 / GCT1015-05 / GOG-3024
Number: 18-35
Full Title:

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer (ENGOT cx8)

Principal Investigator: Dr Dearbhaile Collins
Type: Industry Sponsored
Sponsor:

Seagen

Recruitment Started: Global:
Ireland: February 27, 2019
Global Recruitment Target: 220, 30 patients on current Arm
Ireland Recruitment Target: